QNCX
NASDAQQuince Therapeutics Inc.
Price$1.03-0.02 (-2.37%)
01:30 PM07:45 PM
News · 26 weeks42+33%
2025-12-072026-05-31
Mix2190d
- SEC Filings14(67%)
- Other6(29%)
- Earnings1(5%)
Latest news
25 items- SECSEC Form 8-K filed by Quince Therapeutics Inc.8-K - Quince Therapeutics, Inc. (0001662774) (Filer)
- SECAmendment: Quince Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K/A - Quince Therapeutics, Inc. (0001662774) (Filer)
- PRUPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILDData from Phase 2a study of LAM-001 on top of standard of care in PH-ILD patients with refractory PH demonstrated clinically meaningful improvement in multiple assessments of lung function, including improvement in 6MWD of 67.4 meters and PVR reduction of 33.9% at 24 weeksPhase 2b trial in PH-ILD to initiate in mid-2026, with topline data anticipated in the first quarter of 2028Conference call and webcast today, May 18, 2026, at 10:00 a.m. ET SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (NASDAQ:QNCX) announced Phase 2a data evaluating LAM-001, an inhaled formulation of rapamycin (mTOR inhibitor), in patients with pulmonary arterial hypertension (
- SECQuince Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Quince Therapeutics, Inc. (0001662774) (Filer)
- PRQuince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary PipelineAcquisition includes LAM-001, an inhaled formulation of rapamycin for multiple pulmonary diseases, including pulmonary hypertension associated with interstitial lung disease (PH-ILD) and bronchiolitis obliterans syndrome post lung transplant (BOS)$115 million in upfront financing with the potential to receive up to an additional $72 million upon exercise of accompanying warrantsUpfront proceeds from the private placement and existing cash and cash equivalents at closing are expected to fund operations through the end of 2028 and to support multiple expected milestones, including initiation of a Phase 2b trial in PH-ILD with data anticipated in Q1 2028 and delivery of Phase 2 data in BOS in Q
- PRQuince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILDData from Phase 2a study of LAM-001 on top of standard of care in PH-ILD patients with refractory PH demonstrated clinically meaningful improvement in multiple assessments of lung function, including improvement in 6MWD of 67.4 meters and PVR reduction of 33.9% at 24 weeksPhase 2b trial in PH-ILD to initiate in mid-2026, with topline data anticipated in the first quarter of 2028Conference call and webcast today, May 18, 2026, at 10:00 a.m. ET SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (NASDAQ:QNCX) announced Phase 2a data evaluating LAM-001, an inhaled formulation of rapamycin (mTOR inhibitor), in patients with pulmonary arterial hypertension (
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Quince Therapeutics Inc.SCHEDULE 13G/A - Quince Therapeutics, Inc. (0001662774) (Subject)
- SECSEC Form 10-Q filed by Quince Therapeutics Inc.10-Q - Quince Therapeutics, Inc. (0001662774) (Filer)
- SECSEC Form 8-K filed by Quince Therapeutics Inc.8-K - Quince Therapeutics, Inc. (0001662774) (Filer)
- SECSEC Form DEFA14A filed by Quince Therapeutics Inc.DEFA14A - Quince Therapeutics, Inc. (0001662774) (Filer)
- SECSEC Form DEF 14A filed by Quince Therapeutics Inc.DEF 14A - Quince Therapeutics, Inc. (0001662774) (Filer)
- SECSEC Form 8-K filed by Quince Therapeutics Inc.8-K - Quince Therapeutics, Inc. (0001662774) (Filer)
- SECSEC Form PRE 14A filed by Quince Therapeutics Inc.PRE 14A - Quince Therapeutics, Inc. (0001662774) (Filer)
- SECSEC Form S-8 filed by Quince Therapeutics Inc.S-8 - Quince Therapeutics, Inc. (0001662774) (Filer)
- SECSEC Form 10-K filed by Quince Therapeutics Inc.10-K - Quince Therapeutics, Inc. (0001662774) (Filer)
- SECQuince Therapeutics Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders8-K - Quince Therapeutics, Inc. (0001662774) (Filer)
- SECSEC Form NT 10-K filed by Quince Therapeutics Inc.NT 10-K - Quince Therapeutics, Inc. (0001662774) (Filer)
- SECQuince Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Quince Therapeutics, Inc. (0001662774) (Filer)
- PRQuince Therapeutics Settles Approximately $16.4 Million of DebtQuince Therapeutics, Inc. (NASDAQ:QNCX) today announced the successful settlement of the company's outstanding obligations under its loan from the European Investment Bank (EIB) for a payment of $5.5 million. This marks a material milestone for Quince as the completion of the settlement resolves critical debt obligations and allows the company to advance its restructuring and evaluation of strategic alternatives aimed at maximizing shareholder value. Effective immediately upon the $5.5 million payment, Quince settled outstanding EIB debt obligations of approximately $16.4 million as of March 27, 2026. As a direct result of this $5.5 million payment, all of the company's obligations under
- SECSEC Form 8-K filed by Quince Therapeutics Inc.8-K - Quince Therapeutics, Inc. (0001662774) (Filer)
- SECSEC Form SCHEDULE 13G filed by Quince Therapeutics Inc.SCHEDULE 13G - Quince Therapeutics, Inc. (0001662774) (Subject)
- SECQuince Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events8-K - Quince Therapeutics, Inc. (0001662774) (Filer)
- PRQuince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic AlternativesQuince Therapeutics, Inc. (NASDAQ:QNCX), today announced that it has engaged LifeSci Capital to serve as its exclusive financial advisor to assist in its restructuring and evaluation of strategic alternatives aimed at maximizing shareholder value. Strategic alternatives under consideration may include, but are not limited to, partnerships, joint ventures, mergers, acquisitions, licensing, or other strategic transactions. LifeSci Capital will also act as the company's financial advisor in connection with any restructuring of the company's liabilities. The company does not intend to discuss or disclose further developments during this process unless and until its Board of Directors has appr
- SECSEC Form 8-K filed by Quince Therapeutics Inc.8-K - Quince Therapeutics, Inc. (0001662774) (Filer)
- ANALYSTQuince Therapeutics downgraded by Citizens JMPCitizens JMP downgraded Quince Therapeutics from Mkt Outperform to Mkt Perform
QNCX FAQ
6 questionsWhere does QNCX stock trade?
Quince Therapeutics Inc. (QNCX) is listed on NASDAQ.What sector and industry is QNCX in?
Quince Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Quince Therapeutics Inc. go public?
Quince Therapeutics Inc. (QNCX) completed its IPO in 2019.What are analysts saying about QNCX?
Quince Therapeutics Inc. has had 3 recent analyst actions on file. The most recent action was from Citizens JMP: Mkt Perform on 2026-01-30. Recent price targets range from $900.00 to $1000.00.What companies are similar to QNCX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare QNCX side-by-side with any of them on Quantisnow.How can I track QNCX on Quantisnow?
Quantisnow aggregates Quince Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow QNCX to receive live email and push alerts on every new disclosure.